We proposed that miR-92a-3p impairs FOLFOX (fluorouracil/oxaliplatin) chemotherapy response by upregulating the expression of chemoresistance biomarker genes through the activation of β-catenin and epithelial-mesenchymal transition (EMT)...Furthermore, even though miR-92a-3p affects ERCC2, XRCC1, E-cadherin, and β-catenin mRNA levels, it has no influence on their protein expression. We found that miR-92a-3p does not upregulate the expression of proteins of DNA-repair pathways and other genes involved in FOLFOX chemotherapy resistance.

11 hours ago

Preclinical • Journal

ERCC1 (Excision repair cross-complementation group 1) • ERCC2 (Excision repair cross-complementation group 2) • CDH1 (Cadherin 1) • TYMS (Thymidylate Synthetase) • MTHFR (Methylenetetrahydrofolate Reductase) • DPYD (Dihydropyrimidine Dehydrogenase) • XRCC1 (X-Ray Repair Cross Complementing 1)

5-fluorouracil • oxaliplatin • leucovorin calcium

18h

H2S-driven chemotherapy and mild photothermal therapy induced mitochondrial reprogramming to promote cuproptosis. (PubMed, J Nanobiotechnology)

A multifunctional cascade bioreactor based on the H2S-responsive mesoporous Cu2Cl(OH)3-loaded hypoxic prodrug tirapazamine (TPZ), in which the outer layer was coated with hyaluronic acid (HA) to form TPZ@Cu2Cl(OH)3-HA (TCuH) nanoparticles (NPs), demonstrated a synergistic antitumor effect through combining the H2S-driven cuproptosis and mild photothermal therapy...The enriched Cu2+ induced not only cuproptosis by promoting lipoacylated dihydrolipoamide S-acetyltransferase (DLAT) heteromerization but also performed chemodynamic therapy though catalyzing H2O2 to produce highly toxic hydroxyl radicals ·OH. Therefore, the nanoparticles TCuH offer a versatile platform to exert copper-related synergistic antitumor therapy.

18 hours ago

Journal

DLAT (Dihydrolipoamide S-Acetyltransferase)

Tirazone (tirapazamine)

19h

Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade. (PubMed, J Immunother Cancer)

These data demonstrate that TT is an oncolytic small molecule with multiple targets and confirms that cell death induced by this compound has the potential to augment antitumor responses to immunotherapy.

19 hours ago

Journal • Checkpoint inhibition • Checkpoint block

CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • GSDME (Gasdermin E)

tigilanol tiglate (EBC-46)

19h

Design, synthesis, insilco study and biological evaluation of new isatin-sulfonamide derivatives by using mono amide linker as possible as histone deacetylase inhibitors. (PubMed, Pol Merkur Lekarski)

The synthesized compounds (I, II, III and IV) showed cytotoxicity toward MCF-7 and HepG2 cancer cell lines and their docking analysis provided a preliminary indication that they are viable [HDAC6] candidates.

19 hours ago

Journal • Epigenetic controller

STAT3 (Signal Transducer And Activator Of Transcription 3)

Zolinza (vorinostat)

Jiedu Xiaozheng Yin Inhibits the Progression of Colitis Associated Colorectal Cancer by Stimulating Macrophage Polarization Towards an M1 Phenotype via the TLR4 Pathway. (PubMed, Integr Cancer Ther)

Subsequently, after antagonizing the TLR4 pathway with antagonists (TAK242, PDTC, KG501, SR11302, LY294002), the expression of IL-6, TNF-α, iNOS, and IL-1β mRNA were detected by RT-qPCR. Furthermore, JXY inhibited M1-related molecules such as IL-6, TNF-α, iNOS, and IL-1β after antagonizing the TLR4 pathway. Obviously, JXY could exhibit inhibitory effects on the development of colon tumors in mice with CAC by promoting M1 polarization through TLR4-mediated signaling and impeding M2 polarization of macrophages.

1 day ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)

IL6 expression

LY294002

MiPac: The Role of the Human Microbiome in Patients After Pancreatic Resection. (clinicaltrials.gov)

P=N/A, N=200, Not yet recruiting, St. Antonius Hospital

1 day ago

New trial

Endocannabinoid remodeling in murine cachexic muscle associates with catabolic and metabolic regulation. (PubMed, Biochim Biophys Acta Mol Basis Dis)

Our findings depict an emerging role of the endocannabinoid system in muscle physiology. Future studies should elaborate how this translates into potential therapies to combat cancer cachexia, and other degenerative conditions.

1 day ago

Preclinical • Journal

ATG5 (Autophagy Related 5)

Prospective Study of Extended Robotic Right Hemicolectomy With Complete Mesocolic Excision for Cancer (clinicaltrials.gov)

P=N/A, N=40, Recruiting, Vejle Hospital | Trial primary completion date: Dec 2023 --> Jun 2024

1 day ago

Trial primary completion date

Poorly differentiated mucinous carcinoma of the ascending colon complicated by bilateral ovarian mature cystic teratomas in a 17-year-old female patient: a case report. (PubMed, Surg Case Rep)

We presented a case of locally advanced ascending colon cancer in a 17-year-old female patient. CRC rarely occurs in AYAs. However, the incidence has gradually increased in recent years. It should be considered as a differential diagnosis for young patients with long-term abdominal symptoms of unknown cause.

2 days ago

Journal

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)

BRAF mutation

5-fluorouracil • oxaliplatin

Arnicolide D: a multi-targeted anticancer sesquiterpene lactone-preclinical efficacy and mechanistic insights. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)

Given its multifaceted mechanisms and preclinical efficacy, Arnicolide D warrants further investigation in clinical settings to validate its therapeutic utility against cancer. The evidence presented underscores the need for rigorous pharmacokinetic and toxicological studies to establish safe dosing parameters for future clinical trials.

2 days ago

Preclinical • Review • Journal

STAT3 (Signal Transducer And Activator Of Transcription 3)

Downregulation of NAT1 Expression is Associated with Poor Prognosis and Immune Infiltration in COAD. (PubMed, Pharmgenomics Pers Med)

The findings reveal NAT1's potential as a valuable prognostic biomarker for COAD. Moreover, its associated mechanisms offer insights that might pave the way for therapeutic interventions for COAD patients.

2 days ago

Journal

CEACAM5 (CEA Cell Adhesion Molecule 5) • NAT1 (N-Acetyltransferase 1)

Unveiling the hub genes in the SIGLECs family in colon adenocarcinoma with machine learning. (PubMed, Front Genet)

We conclude SIGLEC-1,15 and CD22 as the most promising hub genes in the SIGLECs family in treating COAD. PCA offers significant enhancement in the prognosis and clinical analyses, while using SOM further unveils the transition phases or potential subtypes of COAD.

2 days ago

Journal • Machine learning

CD22 (CD22 Molecule) • SIGLEC14 (Sialic Acid Binding Ig Like Lectin 14)

Sishen Pill and its active phytochemicals in treating inflammatory bowel disease and colon cancer: an overview. (PubMed, Front Pharmacol)

Modern research has confirmed that Sishen Pill and its active secondary metabolites, such as psoralen, myristicin, evodiamine, and schisandrin, can improve intestinal inflammation and exert antitumor pharmacological effects...Overall, existing evidence suggests the potential of the Sishen pill to improve IBD and suppress inflammation-to-cancer transformation. However, large-scale randomized controlled clinical studies and research on the safety of these clinical applications are urgently required.

2 days ago

Review • Journal

HIF1A (Hypoxia inducible factor 1, alpha subunit)

T-bet Regulates Ion Channels and Transporters and Induces Apoptosis in Intestinal Epithelial Cells. (PubMed, Adv Sci (Weinh))

Herein, a Tet-O-T-bet transgenic mouse strain is generated for doxycycline-inducible T-bet expression in adult animals...Furthermore, ectopic T-bet expression enhances gut epithelial cell apoptosis and markedly suppresses colon cancer development in xenograft models. Collectively, the findings unveil a previously unrecognized role of T-bet in intestinal epithelial cells for inducing apoptosis, diarrhea, and local inflammation, thus implicating its potential as a therapeutic target for the treatment of cancer and inflammatory diseases.

2 days ago

Journal

CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21)

CD4 expression • CD4 overexpression

Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer. (PubMed, J Nanobiotechnology)

Moreover, A6-NP continues to exert the broad anticancer spectrum of Hsp90 inhibitors and displays remarkable targeting ability and anticancer efficacy both in hematological malignancies and solid tumors (with colon tumors as the model cancer) both in vitro and in vivo. Overall, A6-NP, as a simple, biomimetic and active dual-targeting (CD44 and HSP90) nanomedicine, displays high potential for clinical translation.

2 days ago

Journal

CD44 (CD44 Molecule)

CD44 positive

Surgical resection combined with intraperitoneal chemotherapy (CT) is the best treatment for selected patients with Peritoneal Metastases from colon cancer. However, the real role of intraperitoneal CT as a necessary component of this treatment is unknown, despite its proven experimental basis. The main objective of this study is to clarify it, so one group of patients will be treated with surgery + intraperitoneal CT and the other with surgery alone. La resección quirúrgica combinada con quimioterapia (QT) intraperitoneal es el mejor tratamiento para pacientes seleccionados con metástasis peritoneales de cáncer de colon. Sin embargo, se desconoce el papel real de la QT intraperitoneal como componente necesario de este tratamiento, a pesar de su probada base experimental. El objetivo principal de este estudio es aclararlo, por lo que un grupo de pacientes será tratado con cirugía + QT intraperitoneal y el otro solo con cirugía. (clinicaltrialsregister.eu)

P4, N=216, Ongoing, Hospital Universitario de Fuenlabrada

2 days ago

New P4 trial • Surgery

MSI (Microsatellite instability)

mitomycin

This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with a chemotherapy treatment for people with colorectal cancer after all available standard treatments. (clinicaltrialsregister.eu)

P3, N=668, Ongoing, 1Globe Health Institute

2 days ago

New P3 trial • Combination therapy • Metastases

CTNNB1 (Catenin (cadherin-associated protein), beta 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)

5-fluorouracil • irinotecan • leucovorin calcium • napabucasin (BBI608)

Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer. (PubMed, Sci Rep)

Finally, HCT116 and HT29 cells exhibited inhibition of BRD3 gene proliferation and migration, as well as promotion of apoptosis. In patients with COAD, HDAC-related characteristics may be useful in predicting survival and selecting treatment.

2 days ago

Journal • PD(L)-1 Biomarker • IO biomarker • Epigenetic controller

BRD3 (Bromodomain Containing 3)

SoFiT: Study on Fatigue in Colorectal Cancer Survivors, a Lifestyle Intervention (clinicaltrials.gov)

P=N/A, N=184, Active, not recruiting, Wageningen University | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024

3 days ago

Trial completion date • Trial primary completion date

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov)

P2, N=30, Completed, Shanghai Changzheng Hospital | Recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2023

3 days ago

Trial completion • Trial primary completion date • Metastases

Focus V (anlotinib) • Tyvyt (sintilimab)

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging (clinicaltrials.gov)

P1, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Apr 2024

3 days ago

Enrollment open • Trial initiation date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSH2 (MutS Homolog 2)

BRCA2 mutation • BRCA1 mutation

Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis (clinicaltrials.gov)

P=N/A, N=124, Not yet recruiting, Western University, Canada | Initiation date: Jul 2023 --> May 2024

3 days ago

Trial initiation date

The Myc-associated zinc finger protein epigenetically controls expression of interferon-γ-stimulated genes by recruiting STAT1 to chromatin. (PubMed, Proc Natl Acad Sci U S A)

Furthermore, we find that MAZ controls expression of the immunity-related genes by changing the epigenetic landscape in chromatin. Our study reveals an important role for MAZ in regulating immune-related gene expression.

3 days ago

Journal

IFNG (Interferon, gamma) • IRF8 (Interferon Regulatory Factor 8) • AIM2 (Absent In Melanoma 2) • STAT1 (Signal Transducer And Activator Of Transcription 1)

Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis. (PubMed, J Cancer Res Clin Oncol)

Our study showed that cromolyn is a selective and strong drug in inhibiting the proliferation of colon cancer cells. Based on our results, the efficacy of C in vitro analysis (MTT assays and apoptosis), as well as animal studies is competitive with the FDA-approved drug doxorubicin. C is very promising as a low-complication and good-efficacy drug for cancer drug repositioning. This requires clinical research study designs to comprehensively evaluate its anti-cancer effects.

3 days ago

Preclinical • Journal

ANXA5 (Annexin A5)

doxorubicin hydrochloride

Evaluation of the anticancer effects exerted by 5-fluorouracil and heme oxygenase-1 inhibitor hybrids in HTC116 colorectal cancer cells. (PubMed, J Enzyme Inhib Med Chem)

Particularly, compounds inhibit HO-1 activity in cell lysates, increase ROS and the expression of HO-1, SOD, and Nrf2. Moreover, we observed a decrease of pro-caspase and an increase in cleaved PARP-1 and p62, suggesting apoptotic and autophagic cell death and potential application of these drugs as anticancer agents.

3 days ago

Journal • PARP Biomarker

HMOX1 (Heme Oxygenase 1)

5-fluorouracil

The electroneutral Na+-HCO3- cotransporter NBCn1 (SLC4A7) modulates colonic enterocyte pHi, proliferation and migration. (PubMed, Am J Physiol Cell Physiol)

In the migrating Caco2BBe cells, NBCn1 was found at the leading edge and in colocalization with the focal adhesion markers vinculin and paxillin, which suggests that NBCn1 is involved in the establishment of cell-matrix adhesion. Our data highlight the physiological significance of NBCn1 in modulating epithelial pH-homeostasis and cell-matrix interactions in the proliferative region of the colonic epithelium, and unravel the molecular mechanism behind pathological overexpression of this transporter in human colorectal cancers.

3 days ago

Journal

VCL (Vinculin) • SLC4A7 (Solute Carrier Family 4 Member 7)

Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models. (PubMed, Theranostics)

We demonstrate that lena can augment the hRT-induced abscopal effect in mouse solid tumor models in a CD8 T cell- and IFN-I-dependent manner, correlating with enhanced anti-tumor CD8 T cell immunity, DC cross-presentation, and TA-HEC numbers. Our findings may be helpful for the planning of clinical trials in (oligo)metastatic patients.

3 days ago

Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD70 (CD70 Molecule) • GZMB (Granzyme B) • CD86 (CD86 Molecule)

lenalidomide

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review). (PubMed, Oncol Lett)

It summarizes the therapeutics, mechanisms of action, research advances and challenges of targeting CD47. In addition, this paper provides an overview of the latest therapeutic options for targeting CD47, such as chimeric antigen receptor (CAR) T-cells, CAR macrophages and nanotechnology-based delivery systems, which are essential for future clinical research on targeting CD47.

3 days ago

Review • Journal • Tumor cell

CD47 (CD47 Molecule) • CGAS (Cyclic GMP-AMP Synthase)

CD47 expression

Rapid detection of carcinoembryonic antigen by means of an electrochemical aptasensor. (PubMed, iScience)

Atomic force microscopy (AFM) micrographs supported the EIS data, demonstrating a change in IDE surface roughness after each modification step, confirming the successful capture of the target. The potential of this developed EIS aptasensor in detecting CEA in complex samples holds promise.

3 days ago

Journal

CEACAM5 (CEA Cell Adhesion Molecule 5)

Chemotherapeutic potential of betanin/capecitabine combination targeting colon cancer: experimental and bioinformatic studies exploring NFκB and cyclin D1 interplay. (PubMed, Front Pharmacol)

These pathologic manifestations were reduced remarkably in betanin/capecitabine group. Collectively, our findings demonstrated the usefulness of betanin/capecitabine combination in targeting colon cancer and highlighted that betanin is a promising adjuvant therapy to capecitabine in treating colon cancer patients.

3 days ago

Journal

CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IL1B (Interleukin 1, beta)

CCND1 expression

capecitabine

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. (PubMed, J Transl Med)

These finding demonstrated that DB-1310 exerted potent antitumor activities against HER3 + tumors in in vitro and in vivo models, and showed acceptable safety profiles in nonclinical species. Therefore, DB-1310 may be effective for the clinical treatment of HER3 + solid tumors.

3 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

ERBB3 overexpression • ERBB3 positive

Tagrisso (osimertinib) • patritumab deruxtecan (U3-1402) • DB-1310

Single-cell transcriptome analysis profiling lymphatic invasion-related TME in colorectal cancer. (PubMed, Sci Rep)

In this report, we provided a valuable resource and extensive insights into the LI of CRC. Our conclusions can potentially benefit the establishment of highly efficacious therapeutic targets as well as diagnostic biomarkers that improve patient outcomes.

3 days ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CD4 (CD4 Molecule) • GZMK (Granzyme K)

Neoadjuvant strategy for locally advanced colorectal cancer based organ preservation (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)

On the other hand, selective radiotherapy preserves organ function and improves quality of life. This article reviews the neoadjuvant treatment strategies for locally advanced colorectal cancer based on organ-sparing strategies.

4 days ago

Journal • Metastases

MSI (Microsatellite instability)

Organ preservation in locally advanced colorectal cancer with microsatellite instability-high after immunotherapy (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)

Finally, the medication choices of immunotherapy, the treatment regimen, and the follow-up strategy are further discussed. We hope that neoadjuvant immunotherapy could be appropriately applied in MSI-H/dMMR colorectal cancer so that more patients can achieve organ preservation.

4 days ago

Journal • Microsatellite instability • Metastases

MSI (Microsatellite instability)

MSI-H/dMMR

Urolithin A affects cellular migration and modulates matrix metalloproteinase expression in colorectal cancer cells. (PubMed, Cell Biochem Funct)

The findings provided the first indication of the influence of UA on cellular migration and metastasis in colon cancer cells. All of these data showed that UA might be used as an adjuvant therapy in the treatment of various forms of CRC.

5 days ago

Journal

MMP2 (Matrix metallopeptidase 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • MMP1 (Matrix metallopeptidase 1)

An arresten-derived anti-angiogenic peptide triggers apoptotic cell death in endothelial cells. (PubMed, Mol Biol Rep)

It might be suggested that Ars induced apoptosis in endothelial cells through the mitochondrial pathway and had no effect on the cell cycle. Besides, Ars induced apoptosis significantly in vivo. However, further studies are required to confirm the detailed molecular mechanism of Ars, this peptide has the potential to be optimized for clinical translations.

5 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)

Astragali Radix-Curcumae Rhizoma inhibits colon cancer progression and enhances 5-FU efficacy by regulating hypoxia-inducible factors and tumor stem cells (PubMed, Zhongguo Zhong Yao Za Zhi)

The animal and cell models were used in this study to investigate the mechanism of Astragali Radix-Curcumae Rhizoma(HQEZ) in inhibiting colon cancer progression and enhancing the efficacy of 5-fluorouracil(5-FU) by regulating hypoxia-inducible factors and tumor stem cells...Compared with 5-FU(1.38 μmol·L~(-1)) alone, HQEZ(40 mg·mL~(-1)) and 5-FU+HQEZ significantly down-regulated the protein levels of HIF-1α, HIF-2α, and TYMS. In conclusion, HQEZ can inhibit the expression of hypoxia-responsive molecules in colon cancer cells and reduce the properties of cancer stem cells, thereby enhancing the therapeutic effect of 5-FU on colon cancer.

5 days ago

Journal

EGFR (Epidermal growth factor receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • TYMS (Thymidylate Synthetase) • EPAS1 (Endothelial PAS domain protein 1) • SOX2 • YBX1 (Y-Box Binding Protein 1) • DPYD (Dihydropyrimidine Dehydrogenase)

5-fluorouracil

Dual function of activated PPARγ by ligands on tumor growth and immunotherapy. (PubMed, Med Oncol)

These controversial findings may be derived from cancer cell types, conditions, and ligands, since some ligands are independent of PPARγ activity. Therefore, this review discussed the dual role of PPARγ on tumor progression and immunotherapy.

6 days ago

Review • Journal

PPARG (Peroxisome Proliferator Activated Receptor Gamma)

The RNA-binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA. (PubMed, Cancer Med)

The investigation ascertained that RBMS3 inhibits the progression of colon cancer by regulating LIMS1. The inhibitory function of LIMS1 and RBMS3 is closely intertwined in colon cancer, with knocking down LIMS1 being able to rescue the inhibitory effect of RBMS3 overexpression on the functionality of colon cancer cell The discernments delineate RBMS3 as a novel suppressor of cancer via LIMS1, thereby bestowing fresh therapeutic possibilities and illuminating the intricacies of colon cancer.

6 days ago

Journal

LIMS1 (LIM Zinc Finger Domain Containing 1) • RBMS3 (RNA Binding Motif Single Stranded Interacting Protein 3)

Constructing and validating a risk model based on neutrophil-related genes for evaluating prognosis and guiding immunotherapy in colon cancer. (PubMed, J Gene Med)

The low-risk group showed better OS and PFS than the high-risk group in the neutrophil-related gene-based risk model. Patients in the high-risk group presented higher immune infiltration levels and tumor mutational burden and thus may be more responsive to immunotherapy.

6 days ago

Review • Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • MMP3 (Matrix metallopeptidase 3)

Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review. (PubMed, Front Immunol)

He has achieved a progression-free survival of 43 months and is still being followed up at our center. The above results suggest that this therapeutic regimen is a promising treatment modality for the management of pretreated, MSS-type and KRAS-mutated metastatic colorectal cancer although its application to the general public still needs to be validated in clinical trials.

6 days ago

Clinical • Clinical guideline • Retrospective data • Review • Clinical Trial,Phase III • Journal • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD14 (CD14 Molecule)

KRAS mutation

Avastin (bevacizumab) • Tyvyt (sintilimab)